93 results about "Animal tumor" patented technology

New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the α-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

The present invention relates to methods and compositions for treating a neoplasia in a mammal.

The invention provides a humanized PD-L1 tumor cell line MC-38-hPD-L1, a builtanimal tumor model with the same and a method for constructing the humanized PD-L1 tumor cell line. The method particularly includes knocking out animal-origin PD-L1 by the aid of CRISPR-CAS9; carrying out amplification and cultivation to obtain knocked-out cell banks; extracting DNA (deoxyribonucleic acid) and carrying out PCR (polymerase chain reaction) amplification; recycling and cloning amplification products; carrying out over-expression on human-origin PD-L1 in MC-38 cell lines of mPD-L1 KO by the aid of lentivirus systems; packaging lentivirus and screening Puromycin to obtain the humanized MC-38 cell line of PD-L1. The humanized PD-L1 tumor cell line, the animal tumor model and the method have the advantages that as shown by results, high killing efficiency and multiplication capacity are obviously presented by tumor infiltration CD8 T lymphocytes after antibody treatment is carried out, tumor infiltration Treg cells can be obviously inhibited after antibody treatment is carried out, and accordingly the method is proved to be effective and feasible from the aspect of molecular mechanisms.

The present invention relates to a double-stranded RNA and its application for inhibiting mammalian tumor cell. Said invention adopts the RNA interference technique to introduce the externally-synthetic double-stranded RNA into mammalian tumor cell by means of combination of non-viral carrier and / or viral carrier, and can inhibit the expression of epidermal growth factor receptor so as to change NSCLC cell biological character and raise the sensitivity of mammalian tumor cell to radiation therapy and chemical therapy. Said invented double-strand RNA can be used for preparing antitumor biological preparation and antitumor medicine to make direct injection in tumor body in travenous medication for effectively inhibiting tumor growth.

A method for inhibiting growth and / or metastasis of a tumor in a mammal is disclosed. The method comprises administering to a mammal in need thereof an effective amount of stem cells comprising a transgene encoding at least one oncogenic protein, wherein the stem cells are immortal and show no signs of neoplastic transformation, and administering to the mammal a vaccine composition comprising an effective amount of at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one oncogenic protein, and thereby inhibiting growth and / or metastasis of a tumor in the mammal. A therapeutic kit for inhibiting growth and / or metastasis of a tumor in a mammal is also disclosed.

The present invention provides compositions comprising a ligand-nucleic acid nanostructure that promote tumor cell-specific killing and methods of using the compositions. Specially, the invention provides aptamer-nucleic acid nanostructures for treating tumors in a mammal. The methods of making the compositions are also provided.

New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative- cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.

The present invention relates to a kind of amino group or halogen substituted 8-oxy-8H-acenaphthenee[1, 2-b] pyrrolyl-9-nitrile derivatives and their biological use. They are applied mainly in intracorporeal and extracorporeal inducing cell apoptosis and as anticancer compound. These compounds are 3, 6-disubstituted, 3-disubstituted or 6-substituted 8-oxy-8H-acenaphthenee[1, 2-b] pyrrolyl-9-nitrile derivatives. They can induce tumor cell apoptosis and block cell period in the dosage dependent mode within the wide concentration range of 0.01-10 micro mole. The highest activity compound B1 has IC50=0.17 micro mole (0.56 micro gram). When they are used in animal tumor model body, they can inhibit tumor growth obviously in inducing cell apoptosis mode. Therefore, the present invention is one kind of apoptosis inducing agent and antitumor compound with high activity.

The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.

The invention belongs to the technical field of medicine, and particularly relates to an application of a compound separated and extracted from burdock to serving as an STAT3 inhibitor. The compound I can be used for a medicine composition for treating triple negative breast cancer. The compound I and docetaxel are combined into a compound preparation for treating triple negative breast cancer for use. Phosphorylation of STAT3 is remarkably inhibited through burdock aglycone in a cell and animal tumor-bearing model, and the burdock aglycone is free of obvious toxic and side effects on other normal tissues. The application has the advantages of being proper in dosage, remarkable in curative effect, clear in action target, small in toxic and side effect and the like, and has the broad anticancer application prospect in clinic. The compound preparation has the low toxic and side effects. As the toxicity of the burdock aglycone is quite low, and the burdock aglycone and the docetaxel are used as a composition, under the condition that the same anticancer curative effect is achieved, the dosage of the docetaxel can be remarkably decreased, and therefore the toxic and side effects brought by the docetaxel can be further reduced.

A hybrid scientific computer system with processor capable of recording, storing and reprogramming the natural electrical signals of cancer cells as found in tumors of humans and animals. The reprogramming process is designed to create a confounding electrical signal for retransmission into a malignant tumor to damage or shut-down the cellular internal electrical communication system. Altering the electrical charge on the glycocalyx of the outer cell membrane is also part of the treatment by application of ions. Confounding electrical signals are stored in a scientific cancer cell signal processor of the computer system. The invention causes cancer cell death as a medical treatment using ultra-low voltage and amperage encoded signals which are re-programmed from cancer cell communication signals.

New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the alpha-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

The invention discloses a method for in-situ detecting of drug molecules in animal tissues by dual-beam laser mass-spectrography. The method comprises the steps that a drug molecular solution is added into isolated animal tumor tissues, and is frozen and sliced after being diffused adequately; the slices are fixedly arranged on graphite subjected to ultrasonic processing, the graphite is placed into a dual-beam laser mass-spectrometer, and the parsing laser emitted by the dual-beam laser mass-spectrometer enters into an ionization chamber after being focused by the parsing laser and is radiated on the slices; after delay of 18-30 microseconds, a second beam pulse laser is emitted, and is converted into a vacuum ultraviolet laser after being subjected to third harmonic generation in a gas pool; the second beam pulse laser is separated from the vacuum ultraviolet laser by a flat convex lens at a light outlet of the gas pool after the second beam pulse laser and the vacuum ultraviolet laser are focused; the focused vacuum ultraviolet laser enters into the ionization chamber in a direction parallel to a graphite rod and is intersected with the parsing laser; gasification-parsing and ionization are carried out on the isolated tumor tissues; ionized ions fly through a flight tube; and data collecting and processing are carried out.

The invention relates to phenylbutyryl curcumin derivate and application thereof in anti-tumor drug preparation, in particular to 4-(di(2-chloroethyl) amino) phenylbutyryl curcumin, 4,4'-(di(2-chloroethyl)amino) diphenylbutyryl curcumin, pharmaceutically acceptable salts and a preparation method thereof, and applications of 4-(di(2-chloroethyl) amino) phenylbutyryl curcumin, and 4,4'-(di(2-chloroethyl)amino) di phenylbutyryl curcumin in anti-tumor drug preparation. The phenylbutyryl curcumin derivate can be used for (but not limited to) preparing drugs for treating leukemia, skin cancer, gastric cancer, colon cancer, liver cancer, breast cancer or prostatic cancer. The derivate has obvious inhibition on a plurality of animal tumor cell transplanting modules, especially for the human chronic granulocytic leukemia model constructed by NOD-SCID mice inoculated with the human chronic granulocytic leukemia K562 cell stain, the life prolonging rate is obviously enhanced, and the serious toxicity to mice does not exist.

The invention relates to an application of rhizopus nigricans exopolysaccharides in preparation of a medicine for treating or preventing gastrointestinal tumors. The method for preparing the rhizopus nigricans exopolysaccharides comprises the following steps: (1) activating and performing fermental cultivation on rhizopus nigricans with a strain collection number of CGMCC NO.8436, and preparing fermentation liquor; (2) separating and purifying the fermentation liquor, and preparing a crude extracting solution; and (3) discoloring the crude extracting solution by resin columns, oscillating to remove proteins through a Seveage reagent, performing column chromatography purification on Sephadex G-50 sephadex, and preparing the rhizopus nigricans exopolysaccharides. An animal tumor model is established by utilizing the rhizopus nigricans exopolysaccharides, the tumor activity of an entity anti-alimentary system of the rhizopus nigricans exopolysaccharides is explored, the animal tumor experiment anti-tumor result proves that the rhizopus nigricans exopolysaccharides can obviously inhibit growth of tumor blocks of stomach cancer tumor mice and colon cancer tumor mice, and when the rhizopus nigricans exopolysaccharides are combined with modern chemotherapy drug cyclophosphamide, the anti-tumor curative effect is obviously higher than the anti-tumor effect of a single cyclophosphamide drug.

The present invention discloses a new class of 3,11-disubstituted-14-aryl-14H-dibenzo[a,j]xanthene derivatives, and preparation methods thereof, and belongs to the field of chemical synthesis. According to the present invention, 6-hydroxy-2-naphthalene carboxylic acid and aromatic aldehyde are adopted as raw materials, and a series of reactions are performed to synthesize a series of 3,11-disubstituted-14-aryl-14H-dibenzo[a,j]xanthene derivatives. The present invention further provides applications of the 3,11-disubstituted-14-aryl-14H-dibenzo[a,j]xanthene derivatives in antitumor drug preparation. With the present invention, in vitro pharmacological activity screening experiment results show that the synthesized compounds provide proliferation inhibition effects for tumor cells, wherein part of the compounds have significant inhibition effects, and IC50 is less than 1 mum; in vivo experiment results show that part of the compounds can provide animal tumor growth inhibition effects; and the derivatives have characteristics of rational design, simple preparation method and strong practicality.

The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR / MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

The invention relates to the field of new application of compounds, and relates to the field of medicine, in particular to a new application of a small molecular compound SJB2-043 as a medicine for inhibiting Marek's disease virus. According to CEF cell preparation and culture, drug toxicity experiments, inhibition of virus plaques, Q-PCR verification of virus copy number and preliminary animal experiments, the compound SJB2-043 can effectively inhibit replication of Marek's disease viruses at a safe concentration, and the compound SJB2-043 can be used for preparing anti-Marek's disease drugs,muscular hemorrhage, neurological symptoms and animal tumors of toxicity attacking experimental animals are generated, and the product has a good application prospect in poultry breeding.

The invention belongs to the technical field of animal tumor model construction and specifically relates to an immunodeficiency nude mouse model constructed by a lymphoma cell line and capable of being stably passed and a constructing method thereof. The immunodeficiency nude mouse model constructed by the lymphoma cell line and capable of being stably passed is constructed by using an NK cell lymphoma cell line, a T cell lymphoma cell line or a B cell lymphoma cell line; and the immunodeficiency nude mouse model constructed by the lymphoma cell line and capable of being stably passed comprises processes such as corresponding pre-treatment of an object of inoculation and the lymphoma cell line, preparation of a tumor suspension and injection of a nude mouse and tumor cell passage. The constructing method for constructing a lymphoma animal model by using the NK cell lymphoma cell line, the T cell lymphoma cell line or the B cell lymphoma cell line, provided by the invention, has the advantages that a lymphoma cell can be fixed under the skin by using a fixing effect of matrigel so as to guarantee the tumor formation rate of the nude mouse; technical advantages of fast tumor formation and high tumor formation rate are shown; and on the other hand, in the passage process, the lymphoma animal model for passage can be resuscitated at any time and can be directly constructed under the coordination of freezing operation of relevant tumor tissue culture solution.

The invention provides a modeling method for adverse reactions of the digestive tract after chemotherapy, a model and application, and relates to the technical field of pharmacy. The modeling method for the adverse reactions of the digestive tract after chemotherapy comprises the steps of screening the administration dosage of chemotherapy medicine, conducting chemotherapy treatment on an animal tumor model according to the screened administration dosage, and obtaining the model for the adverse reactions of the digestive tract after chemotherapy, wherein with the administration dosage of the screened chemotherapy medicine, enterotoxicity evaluation is carried out on the animal tumor model treated by the chemotherapy medicine, and the digestive tract of the animal tumor model has the adverse reactions. Bad symptoms of the digestive tract in the model obtained by means of the method are caused by the chemotherapy medicine, so that when the model is used for researching and developing medicine for relieving the adverse reactions of the digestive tract after chemotherapy, the symptoms of the model are closer to actual pathological phenomena, accurate screening of the medicine and researching on the mechanism of the screened medicine for relieving the adverse reactions of the digestive tract after chemotherapy are facilitated.